Haleon (ADR) (HLN)
Sells everyday-health brands assembled from the consumer portfolios of GSK, Novartis and Pfizer.
Something off on this page? Send us feedback.
Sells everyday-health brands including Advil, Centrum, Theraflu and Otrivin. The portfolio was assembled through GSK's combinations with Novartis and Pfizer before its independent listing, and the business remains shaped by product innovation, supply-chain execution and inherited contractual dependencies.
Brings together consumer-health brands such as Advil, Centrum, Theraflu, Otrivin and Excedrin, with operations focused exclusively on everyday health rather than prescription pharmaceuticals or diversified consumer categories.
The portfolio was assembled inside GSK through combinations with Novartis and Pfizer, then separated as an independent business in 2022. Product innovation, manufacturing-footprint rationalisation, supply-chain optimisation and continued portfolio pruning shape the operating model.
Former parents have fully exited their holdings, leaving a fully public shareholder base. The business also inherits contractual dependencies from its joint-venture history, including a disputed interpretation of indemnification obligations tied to US Zantac litigation involving predecessor parents.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jan 23, 2026 | Barclays | Upgrade | ||
| Sep 16, 2025 | Barclays | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.09B · Total debt $10.94B · Total assets $43.19B · Shareholders' equity $21.71B
- Revenue
- $7.53B
- Operating income
- $1.79B
- Net income
- $1.02B
Reported in GBP, converted at the latest exchange rate
HistoryDividendAnnual yield
| Institutions | 13.22% | 591.91M ADS | |
|---|---|---|---|
| 649 holders · as of Jun 30, 2026 | |||
| Strategic holders | 13.35% | 597.66M ADS | |
| 1 holder · as of Jul 27, 2022 | |||
| Other | 73.43% | 3.29B ADS | |
| remainder | |||
4.48B ADS (1 ADS = 2 ordinary shares) as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
GSK plcStrategic | 13.35% | 597.66M | filed Jul 27, 2022 |
Dodge & CoxInstitution | 3.35% | 149.93M ADS | as of Jun 30, 2026 |
FMR LLCInstitution | 2.70% | 120.99M ADS | as of Jun 30, 2026 |
Clearbridge Investments, LLCInstitution | 0.72% | 32.34M ADS | as of Jun 30, 2026 |
Morgan StanleyInstitution | 0.43% | 19.46M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Kenvue
Broad consumer-health rival across pain, respiratory and oral care
- Procter & Gamble
Scaled rival in oral care and selected everyday-health categories
- Colgate-Palmolive
Global toothpaste leader challenging therapeutic oral-health brands
- Church & Dwight
Focused challenger in oral care and cold-relief niches
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Haleon (ADR) | $9.26 | −1.12% | $41.22B | 19.5 | — | 2.8 | +3.7% |
| Kenvue | $17.87 | +1.13% | $33.93B | 20.3 | 15.0 | 2.2 | +3.0% |
| Procter & Gamble | $147.55 | +1.01% | $347.33B | 22.1 | 21.1 | 4.0 | +1.5% |
| Colgate-Palmolive | $86.91 | +0.75% | $69.02B | 34.2 | 22.2 | 3.3 | +4.9% |
| Church & Dwight | $96.07 | +0.61% | $22.62B | 30.8 | 24.6 | 3.6 | +1.6% |
| Median | 26.4 | 21.6 | 3.5 | +2.3% |